U.S. FDA Approves New Malaria Treatment Effective In One Dose

CNBC: Gates Foundation CEO: FDA’s approval of single-dose drug to fight malaria
“Sue Desmond-Hellman, Gates Foundation CEO, talks about the importance of a new drug, Krintafel (tafenoquine) that offers hope of a radical cure for malaria. Also Desmond-Hellman shares her thought on preparing for the next pandemic threat…” (7/27).

NPR: New Drug Wipes Out Malaria In A Single Dose — But There’s One Hitch
“…On Friday, the U.S. Food and Drug Administration approved a drug to cure a type of malaria that’s been hard to stop. Called Plasmodium vivax, the parasite can hide out in a person’s liver for months and cause multiple rounds of malaria — even after being treated. … But there’s just one big hitch: To use tafenoquine, doctors and nurses need a sophisticated test that’s not available in many poor places. In certain people, tafenoquine can cause red blood cells to burst open and die. As a result, people can became anemic, and in some instances, this can be lethal…” (Doucleff, 7/26).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.